Total medical devices industry venture financing deals in Q3 2019 worth $2.26bn were announced globally, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 23.3% over the previous quarter and a drop of 6.6% when compared with the last four-quarter average, which stood at $2.42bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $1.34bn. At the country level, the US topped the list in terms of deal value at $1.33bn.
In terms of volumes, North America emerged as the top region for medical devices industry venture financing deals globally, followed by Europe and then Asia-Pacific.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe top country in terms of venture financing deals activity in Q3 2019 was the US with 168 deals, followed by China with 26 and the UK with 14.
In 2019, as of the end of Q3 2019, medical devices venture financing deals worth $7.5bn were announced globally, marking a decrease of 1.9% year on year.
Medical devices industry venture financing deals in Q3 2019: Top deals
The top five medical devices industry venture financing deals accounted for 25.6% of the overall value during Q3 2019.
The combined value of the top five medical devices venture financing deals stood at $577.67m, against the overall value of $2.26bn recorded for the month.
The top five medical devices industry deals of Q3 2019 tracked by GlobalData were:
1) Cambridge Innovation Capital, Escala Capital Investments Cyprus, LGT Impact Ventures, Silk Road Fund and Watrium’s $242.67m venture financing of CMR Surgical
2) The $160m venture financing of Freenome by American Cancer Society, Andreessen Horowitz, Data Collective Venture Capital, Verily Life Sciences, GV Management Co, Kaiser Permanente Ventures, Perceptive Advisors, Polaris Partners, RA Capital Management, Roche Venture Fund, Section 32 and T. Rowe Price Associates
3) ArrowMark Partners, Eventide Asset Management, Farallon Capital Management, Perceptive Advisors, RTW Investments and Soleus Capital Management’s $63m venture financing of Beta Bionics
4) The $60m venture financing of Healthy io by Aleph Venture Capital, Ansonia Holdings Singapore, Joy Capital and Samsung NEXT Ventures
5) Dreamers Fund, KPCB Green Growth Fund, Lowercase Capital, Reproductive Health Investors Alliance, TriplePoint Capital, Union Square Ventures and Y Combinator Management’s venture financing of Nurx for $52m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
